Glenmark Life Sciences Q2 FY23 Investor Presentation

Q2 FY23 investor presentation for Glenmark Life Sciences Ltd covering financial performance with revenue of INR 5,093 mn, EBITDA margins at 30.2%, and gross margins improved to 52.9%. Highlights include completion of generic API capex at Dahej with 240KL capacity expansion, brownfield expansion for oncology plant, and 27% QoQ growth in CDMO business with commercial production commencing Q3 FY23.